867165-55-7

Usage

Structure

Isoindoline-1,3-dione derivative with a 3-chloropyrazine moiety

Usage

Medicinal chemistry and drug discovery, potential drug candidate for the treatment of various diseases

Application

Research and development as a building block for the synthesis of novel chemical entities with potential biological activity

Significance

Unique structure and potential pharmacological properties, interesting target for further investigation and development in the pharmaceutical industry.

Upstream product

• 1074-82-4 potassium phtalimide 
• 45660-95-5 2-chloro-3-(chloromethyl)pyrazine 
• 14508-49-7 2-chloropyrazin 
• 19194-55-9 O-ethyl S-phthalimidomethyl dithiocarbonate 
• 95-58-9 2-chloro-3-methylpyrazine 
• 1289386-07-7 2-(3-chloropyrazinyl)methyl bromide 
• 136918-14-4 phthalimide 
• 89283-32-9 (3-chloropyrazin-2-yl)methanol 

Downstream Products

• 1320266-92-9 8-chloro-1-iodo-3-isopropylimidazo[1,5-a]pyrazine 
• 1320266-94-1 1-iodo-3-isopropylimidazo[1,5-a]pyrazin-8-amine 
• 1320266-96-3 C₁₀H₁₄ClN₃O 
• 1320266-90-7 8-chloro-3-isopropylimidazo[1,5-a]pyrazine 
• 1418307-17-1 benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1418307-18-2 (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)-1-pyrrolidinecarboxylic acid benzyl ester 
• 1420478-87-0 benzyl (2S)-2-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1420478-88-1 benzyl (2S)-2-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate 
• 1419221-77-4 benzyl (3R)-3-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 1419221-78-5 benzyl (3R)-3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 1419221-79-6 benzyl (3R)-3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 
• 1419221-80-9 benzyl (R)-3-(8-amino-1-bromoimidazo[1,5-a]-pyrazin-3-yl)piperidine-1-carboxylate 
• 1418307-23-9 benzyl (2S)-2-([(3-chloropyrazin-2-yl)methyl]carbamoyl)piperidine-1-carboxylate 
• 1419221-81-0 benzyl (3R)-3-(8-amino-1-(4-[(pyridin-2-yl)carbamoyl]phenyl)imidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Xanthate-mediated intermolecular alkylation of pyrazines

An expedient approach for the intermolecular C-H functionalization of pyrazines and other heteroarenes by the radical chemistry of xanthates is reported. Incorporation of a multitude of functional alkyl groups onto these heteroarenes proceeds in good yiel

The compounds of structure containing conjugated zincon, its pharmaceutical composition and use thereof (by machine translation)

The present invention relates to compounds having a structure containing conjugated zincon, its pharmaceutical composition and use, and in particular relates to the general formula (I) or a salt thereof to the compound represented by the, pharmaceutical compositions thereof, and its as BTK inhibitors and/or B cell activation inhibitor, for the prevention or treatment B cell activity with abnormal and/or the use of the BTK-related diseases. The compounds of lymphoma, breast cancer, liver cancer, colon cancer, gastric cancer, such as lung cancer and cervical cancer cell has better lethal effect, note has potential for the treatment of cancer and self-immune diseases related to potential. (by machine translation)

Compound used as Bruton tyrosine kinase inhibitor, and preparation method and application of compound

The invention provides a compound with a structure shown as the formula (I), or an isomer, pharmaceutically acceptable solvate and salt thereof, which is used as the Bruton tyrosine kinase inhibitor. The Bruton tyrosine kinase inhibitor has higher inhibit

COMPOSITIONS AND METHODS FOR TREATING TOXOPLASMOSIS. CRYPTOSPORIDIOSIS AND OTHER APICOMPLEXAN PROTOZOAN RELATED DISEASES

Compositions and methods for the treatment of toxoplasmosis-, caused by the infectious eukaryotic parasite Toxoplasma gondii (T, gondii) and for the treatment of ciyptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C parvuai) and Cnγtosporidium homimus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpDPKS) using pyrazolopyriinidine and/or imidazo[l,5-a]pyraziαe inhibitors, of the formula.(I), wherein the variables X. Y, Z, L. R1. and R3 are defined herein.

Process to prepare substituted imidazopyrazine compounds

A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.